Brief: Medesis Pharma FY EBIT Loss Widens To EUR 3.244 Mln

Medesis Pharma SA

17/04/2023 07:26

April 17 (Reuters) - Medesis Pharma SA  ALMDP.PA :
    * MEDESIS PHARMA ACTIVITIES & ANNUAL RESULTS 2022
    * DEBTS AS OF DECEMBER 31, 2022, AMOUNT TO 2,328,222 EUROS
COMPARED TO 2,074,632 EUROS IN 2021
    * FY 2022, MEDESIS PHARMA DID NOT GENERATE ANY REVENUES,
CONTINUED
TO DEVELOP ITS CLINICAL PROGRAMS AND RESEARCH
    * FY 2022 EBIT LOSS OF EUR 3.244 MILLION VERSUS LOSS OF EUR
3.215
MILLION YEAR AGO
    * FY 2022 COMPANY'S SHAREHOLDERS' EQUITY SHOWS LOSS OF
1,057,832
EUROS IN CONNECTION WITH LOSSES OF LAST TWO YEARS
    * FY 2022 NET LOSS OF EUR 2.749 MILLION VERSUS LOSS OF EUR
2.647
MILLION YEAR AGO
    * IN 2023, MEDESIS AIMS TO CONTINUE DEVELOPING ITS PRIORITY
PROGRAMS AND ROLLING OUT ITS COLLABORATIVE ONCOLOGY AND
NEURODEGENERATIVE DISEASES

Source: bit.ly/41sqBJ2
Further company coverage:  ALMDP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;))